<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937921</url>
  </required_header>
  <id_info>
    <org_study_id>80969</org_study_id>
    <nct_id>NCT03937921</nct_id>
  </id_info>
  <brief_title>Dotarem Evaluation for Myocardial Perfusion CMR</brief_title>
  <official_title>Dotarem Evaluation for Myocardial Perfusion CMR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to investigate the signal intensity and relaxation rate&#xD;
      characteristics of gadoterate meglumine (Dotarem, Guerbet, USA) enhanced myocardium during&#xD;
      rest and stress perfusion cardiovascular magnetic resonance (CMR) compared to gadobutrol&#xD;
      (Gadavist) to prove that Dotarem provides constantly high myocardial relaxation necessary for&#xD;
      accurate quantitative perfusion evaluation.&#xD;
&#xD;
      The purpose of this study is to compare two types of contrast that patients receive during&#xD;
      cardiac MRI scans to visualize the blood flow in the cardiac muscle. Both contrasts are used&#xD;
      in standard of care procedures, and the one administered for each patient will be randomly&#xD;
      selected. The length of the MRI study all procedures are the same as the clinically indicated&#xD;
      scan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal of this study is to investigate the signal intensity and relaxation rate&#xD;
      characteristics of gadoterate meglumine (Dotarem, Guerbet, USA) enhanced myocardium during&#xD;
      rest and stress perfusion cardiovascular magnetic resonance (CMR) compared to gadobutrol&#xD;
      (Gadavist) to prove that Dotarem provides constantly high myocardial relaxation necessary for&#xD;
      accurate quantitative perfusion evaluation. Within this overall goal, the following specific&#xD;
      aims will be pursued:&#xD;
&#xD;
        -  Aim 1: To test the hypothesis that the signal intensity enhancement during Dotarem&#xD;
           myocardial stress/rest perfusion is relatively constant, providing linear and stable&#xD;
           enhancement in the myocardium, and is not inferior compared to gadobutrol (Gadavist).&#xD;
&#xD;
        -  Aim 2: To test the hypothesis that the relaxation rate enhancement during Dotarem&#xD;
           myocardial rest perfusion is uniform in the myocardium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Signal intensity of gadoterate meglumine during perfusion cardiovascular magnetic resonance</measure>
    <time_frame>1 year</time_frame>
    <description>Characteristics of signal intensity changes and absolute myocardial blood flow using the MASS Research Software; signal intensity-time curves from the perfusion data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relaxation rate characteristics of gadoterate meglumine during perfusion cardiovascular magnetic resonance</measure>
    <time_frame>1 year</time_frame>
    <description>The uniformity of T1 and R1 (inverse T1) evaluated using the MASS Research Software; equilibrium T1 maps generated by pre-contrast T1 and repeat inversion recovery images during the perfusion of the coronary arteries</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Myocardial Perfusion Imaging</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>Group 1 - Dotarem</arm_group_label>
    <description>Group 1 (n=30) will receive the clinically approved gadoterate meglumine (Dotarem, 0.1mmol/kg) as the contrast agent for their clinical perfusion study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Gadavist</arm_group_label>
    <description>Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as the contrast agent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadavist 15Ml Solution for Injection</intervention_name>
    <description>Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent. The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups. In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.</description>
    <arm_group_label>Group 2 - Gadavist</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        There will not be any eligibility criteria for any subpopulations. In addition, there will&#xD;
        not be any targeted involvement of special classes of subjects, such as fetuses, neonates,&#xD;
        pregnant women, children, prisoners, institutionalized individuals, or others who may be&#xD;
        considered vulnerable populations. All race and ethnicities and both genders will be&#xD;
        considered for inclusion into the study. Subjects under the age of 18 will not be&#xD;
        considered for inclusion into this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Aim 1&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
        To be eligible for the study: (All answers must be &quot;YES&quot; for subject to be eligible.)&#xD;
&#xD;
          1. Subject must be referred for a clinically indicated contrast-enhanced stress&#xD;
             myocardial perfusion MRI scan out of concern of suspected myocardial ischemia.&#xD;
&#xD;
          2. Subject must be older than 18 years of age.&#xD;
&#xD;
          3. Subject must provide written informed consent prior to any study-related procedures&#xD;
             being performed.&#xD;
&#xD;
          4. Subject must be willing to comply with all clinical study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of the following excludes subjects from the study: (All answers must be &quot;NO&quot;&#xD;
        for subject to be eligible.)&#xD;
&#xD;
          1. Subject is a pregnant or nursing female. Exclude the possibility of pregnancy:&#xD;
&#xD;
               -  By testing (serum or urine beta HCG) within 24 hours before study date, or&#xD;
&#xD;
               -  By surgical sterilization, or&#xD;
&#xD;
               -  Post-menopausal, with minimum one (1) year history without menses.&#xD;
&#xD;
          2. Subject has an implanted cardiac pacemaker or implantable defibrillator.&#xD;
&#xD;
          3. Subject has a ferromagnetic vascular clip.&#xD;
&#xD;
          4. Subject has a neurostimulation system (e.g. TENS-Unit).&#xD;
&#xD;
          5. Subject has any type of cochlear implant.&#xD;
&#xD;
          6. Subject has ocular foreign body (e.g. metal shavings).&#xD;
&#xD;
          7. Subject carries any implanted device (e.g. insulin pump, drug infusion device).&#xD;
&#xD;
          8. Subject has shrapnel, bullet, or other type of metal fragments within the body.&#xD;
&#xD;
          9. Subject has an acute psychiatric disorder or is cognitively impaired.&#xD;
&#xD;
         10. Subject is using or is dependent on substances of abuse.&#xD;
&#xD;
         11. Subject is unwilling to comply with the requirements of the protocol.&#xD;
&#xD;
         12. Subject is in acute unstable condition.&#xD;
&#xD;
         13. Subject has an allergy against gadolinium based contrast agents or pharmaceutical&#xD;
             stressors used in this study.&#xD;
&#xD;
         14. Subject has impaired renal function (creatinine &gt; 1.5 mg/dl).&#xD;
&#xD;
         15. Subject presenting with acute coronary syndrome.&#xD;
&#xD;
         16. Positive cardiac enzymes positive troponin, CK-MB, or myosin&#xD;
&#xD;
         17. ST-elevations, new transient ST changes greater than 0.05mV or T- wave inversions with&#xD;
             symptoms&#xD;
&#xD;
        Aim 2&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
        To be eligible for the study: (All answers must be &quot;YES&quot; for subject to be eligible.)&#xD;
&#xD;
          1. Subject must be referred for a clinically indicated contrast-enhanced stress&#xD;
             myocardial perfusion MRI scan out of concern of suspected myocardial ischemia.&#xD;
&#xD;
          2. Subject must be older than 18 years of age.&#xD;
&#xD;
          3. Subject must provide written informed consent prior to any study-related procedures&#xD;
             being performed.&#xD;
&#xD;
          4. Subject must be willing to comply with all clinical study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of the following excludes subjects from the study: (All answers must be &quot;NO&quot;&#xD;
        for subject to be eligible.)&#xD;
&#xD;
          1. Subject is a pregnant or nursing female. Exclude the possibility of pregnancy:&#xD;
&#xD;
               -  By testing (serum or urine beta HCG) within 24 hours before study date, or&#xD;
&#xD;
               -  By surgical sterilization, or&#xD;
&#xD;
               -  Post-menopausal, with minimum one (1) year history without menses.&#xD;
&#xD;
          2. Subject has an implanted cardiac pacemaker or implantable defibrillator.&#xD;
&#xD;
          3. Subject has a ferromagnetic vascular clip.&#xD;
&#xD;
          4. Subject has a neurostimulation system (e.g. TENS-Unit).&#xD;
&#xD;
          5. Subject has any type of cochlear implant.&#xD;
&#xD;
          6. Subject has ocular foreign body (e.g. metal shavings).&#xD;
&#xD;
          7. Subject carries any implanted device (e.g. insulin pump, drug infusion device).&#xD;
&#xD;
          8. Subject has shrapnel, bullet, or other type of metal fragments within the body.&#xD;
&#xD;
          9. Subject has an acute psychiatric disorder or is cognitively impaired.&#xD;
&#xD;
         10. Subject is using or is dependent on substances of abuse.&#xD;
&#xD;
         11. Subject is unwilling to comply with the requirements of the protocol.&#xD;
&#xD;
         12. Subject is in acute unstable condition.&#xD;
&#xD;
         13. Subject has an allergy against gadolinium based contrast agents used in this study.&#xD;
&#xD;
         14. Subject has impaired renal function (creatinine &gt; 1.5 mg/dl).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danielle Dargis</last_name>
    <phone>843-876-3185</phone>
    <email>dargis@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tyler Leonard</last_name>
    <phone>843-876-4922</phone>
    <email>leonarty@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Dargis</last_name>
      <phone>843-876-4922</phone>
      <email>dargis@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tyler Leonard</last_name>
      <phone>843-876-4922</phone>
      <email>leornarty@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>U. Joseph Schoepf</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akos Varga-Szemes</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>U. Joseph Schoepf, MD</investigator_full_name>
    <investigator_title>Director of the Division of Cardiovascular Imaging</investigator_title>
  </responsible_party>
  <keyword>Signal intensity enhancement</keyword>
  <keyword>Relaxation rate enhancement</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03937921/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03937921/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

